TY - JOUR
T1 - Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia
T2 - As it pertains to the recently published REDUCE-IT trial
AU - Sheikh, Omar
AU - Vande Hei, Anthony G.
AU - Battisha, Ayman
AU - Hammad, Tarek
AU - Pham, Son
AU - Chilton, Robert
N1 - Publisher Copyright:
© 2019 The Author(s).
PY - 2019/6/24
Y1 - 2019/6/24
N2 - Heart disease continues to affect health outcomes globally, accounting for a quarter of all deaths in the United States. Despite the improvement in the development and implementation of guideline-directed medical therapy, the risk of adverse cardiac events remains substantially high. Historically, it has been debated whether omega-3 polyunsaturated fatty acids provide clinical benefit in cardiac disease. The recently published REDUCE-IT trial demonstrated a statistically significant absolute risk reduction of 4.8% in its primary endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina) with the use of icosapent ethyl, which is a highly purified eicosapentaenoic acid (EPA) ethyl ester. However, the mechanism of action of omega-3 fatty acids is not commonly discussed. Moreover, the use of EPA was not without risk, as the incidence of atrial fibrillation was increased along with a trend towards increased bleeding risk. Thus, our aim is to help explain the function of purified EPA ethyl ester, especially at the molecular level, which will ultimately lead to a better understanding of their clinically observable effects.
AB - Heart disease continues to affect health outcomes globally, accounting for a quarter of all deaths in the United States. Despite the improvement in the development and implementation of guideline-directed medical therapy, the risk of adverse cardiac events remains substantially high. Historically, it has been debated whether omega-3 polyunsaturated fatty acids provide clinical benefit in cardiac disease. The recently published REDUCE-IT trial demonstrated a statistically significant absolute risk reduction of 4.8% in its primary endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina) with the use of icosapent ethyl, which is a highly purified eicosapentaenoic acid (EPA) ethyl ester. However, the mechanism of action of omega-3 fatty acids is not commonly discussed. Moreover, the use of EPA was not without risk, as the incidence of atrial fibrillation was increased along with a trend towards increased bleeding risk. Thus, our aim is to help explain the function of purified EPA ethyl ester, especially at the molecular level, which will ultimately lead to a better understanding of their clinically observable effects.
KW - Diabetes mellitus
KW - Hyperlipidemia
KW - Hypertriglyceridemia
KW - Omega-3 polyunsaturated fatty acids
UR - http://www.scopus.com/inward/record.url?scp=85068127930&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068127930&partnerID=8YFLogxK
U2 - 10.1186/s12933-019-0887-0
DO - 10.1186/s12933-019-0887-0
M3 - Review article
C2 - 31234885
AN - SCOPUS:85068127930
SN - 1475-2840
VL - 18
JO - Cardiovascular Diabetology
JF - Cardiovascular Diabetology
IS - 1
M1 - 84
ER -